CSL Behring's recently approved gene therapy for haemophilia B Hemgenix has joined the swelling ranks of new medicines that are bundled with a companion app to support the
CSL has fleshed out the data from its phase 3 trial of garadacimab, a once-monthly therapy for hereditary angioedema (HAE), preparing regulatory filings and an attempt to
CSL and uniQure’s gene therapy for haemophilia B has been approved by the European Commission, ushering in a new era of therapy for patients with the bleeding disorder in
CSL's gene therapy for haemophilia B has been recommended for approval by the EMA's human medicine committee, setting up a decision by the European Commission early next year.
In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio